{"id":59850,"date":"2026-03-18T14:06:52","date_gmt":"2026-03-18T06:06:52","guid":{"rendered":"https:\/\/flcube.com\/?p=59850"},"modified":"2026-03-18T14:06:53","modified_gmt":"2026-03-18T06:06:53","slug":"astrazeneca-secures-eu-approval-for-imfinzi-in-gastric-cancer-perioperative-regimen-cuts-death-risk-22-in-matterhorn-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59850","title":{"rendered":"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial"},"content":{"rendered":"\n<p><strong>AstraZeneca PLC<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NASDAQ: AZN<\/a>) announced <strong>European Union marketing approval<\/strong> for <strong>Imfinzi (durvalumab)<\/strong> in combination with <strong>FLOT chemotherapy<\/strong> for <strong>resectable early\u2011stage and locally advanced gastric cancer and gastroesophageal junction (GEJ) cancer<\/strong>, expanding the PD\u2011L1 inhibitor&#8217;s perioperative oncology portfolio with demonstrated survival benefits across all PD\u2011L1 expression levels.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>European Union (EMA\/EC approval)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Imfinzi (durvalumab) \u2013 PD\u2011L1 inhibitor<\/td><\/tr><tr><td><strong>Combination Regimen<\/strong><\/td><td>FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, docetaxel)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Resectable early\u2011stage and locally advanced gastric\/GEJ cancer (Stage II, III, IVA)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adult patients<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>Approved US, EU; under review Japan and other markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-matterhorn-phase-iii\">Clinical Evidence \u2013 MATTERHORN Phase III<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Imfinzi + FLOT<\/th><th>FLOT Alone<\/th><th>Clinical Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Event\u2011Free Survival (EFS) Risk Reduction<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><td><strong>29% reduction<\/strong> in progression\/recurrence\/death risk<\/td><\/tr><tr><td><strong>Median EFS<\/strong><\/td><td>Not reached<\/td><td>32.8 months<\/td><td>Durability signal<\/td><\/tr><tr><td><strong>12\u2011Month EFS Rate<\/strong><\/td><td>78.2%<\/td><td>74.0%<\/td><td><strong>+4.2 percentage points<\/strong><\/td><\/tr><tr><td><strong>24\u2011Month EFS Rate<\/strong><\/td><td>67.4%<\/td><td>58.5%<\/td><td><strong>+8.9 percentage points<\/strong><\/td><\/tr><tr><td><strong>Overall Survival Risk Reduction<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><td><strong>22% reduction<\/strong> in death risk<\/td><\/tr><tr><td><strong>3\u2011Year Survival Rate<\/strong><\/td><td>69%<\/td><td>62%<\/td><td><strong>+7 percentage points<\/strong><\/td><\/tr><tr><td><strong>PD\u2011L1 Status<\/strong><\/td><td>Benefit observed<\/td><td>\u2013<\/td><td><strong>Independent of PD\u2011L1 expression<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Survival Curve Dynamics:<\/strong> Progressive separation at each prespecified OS time point indicates <strong>magnitude of benefit increases over time<\/strong><\/li>\n\n\n\n<li><strong>Biomarker Agnostic:<\/strong> OS benefit demonstrated regardless of tumor PD\u2011L1 expression status \u2013 broad patient population applicability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-amp-commercial-context\">Strategic &amp; Commercial Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Imfinzi Position<\/th><th>Market Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Perioperative Paradigm<\/strong><\/td><td>First PD\u2011L1 inhibitor approved for perioperative gastric\/GEJ cancer in EU<\/td><td>Establishes standard\u2011of\u2011care position in curative\u2011intent setting vs. adjuvant\/post\u2011surgical competitors<\/td><\/tr><tr><td><strong>FLOT Combination<\/strong><\/td><td>Integrated with established neoadjuvant chemotherapy backbone<\/td><td>Leverages existing surgical oncology workflows; no regimen disruption<\/td><\/tr><tr><td><strong>Geographic Expansion<\/strong><\/td><td>EU approval follows US nod; Japan\/other markets pending<\/td><td>Global perioperative gastric cancer franchise build\u2011out<\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>22% OS benefit vs. chemotherapy alone; PD\u2011L1 agnostic efficacy<\/td><td>Differentiates from nivolumab\u2011based regimens with biomarker\u2011restricted labels<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gastric Cancer Market Dynamics:<\/strong> Gastric cancer represents <strong>fifth most common cancer globally<\/strong> (~1 million new cases annually); resectable Stage II\u2011IVA population in EU\/US\/Japan totals ~150,000 patients\/year with limited perioperative immunotherapy options prior to Imfinzi approval.<\/li>\n\n\n\n<li><strong>MATTERHORN Clinical Impact:<\/strong> 29% EFS risk reduction and 22% OS mortality benefit in curative\u2011intent setting positions Imfinzi as potential new standard; &#8220;perioperative&#8221; (pre\u2011+ post\u2011surgical) approach captures patient population earlier than adjuvant\u2011only competitors.<\/li>\n\n\n\n<li><strong>AstraZeneca Oncology Portfolio Synergies:<\/strong> Imfinzi gastric approval complements existing indications (Stage III NSCLC, extensive\u2011stage SCLC, biliary tract cancer); perioperative strategy aligns with Enhertu (trastuzumab deruxtecan) in HER2+ gastric cancer for comprehensive gastric\/GEJ franchise coverage.<\/li>\n\n\n\n<li><strong>Revenue Trajectory:<\/strong> Perioperative gastric cancer indication adds estimated <strong>US$400\u2011600 million<\/strong> annual peak sales potential (2028\u20112030) assuming 25\u201130% market share in addressable EU\/US populations; Japan approval (expected H2 2026) adds further upside.<\/li>\n\n\n\n<li><strong>Regulatory Momentum:<\/strong> EU approval validates MATTERHORN data package for additional market submissions; China NMPA submission anticipated 2026\u20112027 given gastric cancer incidence priority and AstraZeneca&#8217;s established China oncology infrastructure.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercialization expectations, market penetration projections, and regulatory expansion timelines for Imfinzi in gastric cancer. Actual results may differ due to risks including competitive dynamics, reimbursement negotiations, and physician adoption rates in perioperative oncology.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca PLC (NASDAQ: AZN) announced European Union marketing approval for Imfinzi (durvalumab) in combination with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59853,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[130,16,871,18,15],"class_list":["post-59850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astrazeneca","tag-cancer","tag-nasdaq-azn","tag-pd-1-l1","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca PLC (NASDAQ: AZN) announced European Union marketing approval for Imfinzi (durvalumab) in combination with FLOT chemotherapy for resectable early\u2011stage and locally advanced gastric cancer and gastroesophageal junction (GEJ) cancer, expanding the PD\u2011L1 inhibitor&#039;s perioperative oncology portfolio with demonstrated survival benefits across all PD\u2011L1 expression levels.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59850\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca PLC (NASDAQ: AZN) announced European Union marketing approval for Imfinzi (durvalumab) in combination with FLOT chemotherapy for resectable early\u2011stage and locally advanced gastric cancer and gastroesophageal junction (GEJ) cancer, expanding the PD\u2011L1 inhibitor&#039;s perioperative oncology portfolio with demonstrated survival benefits across all PD\u2011L1 expression levels.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59850\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T06:06:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-18T06:06:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1804.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59850#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59850\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial\",\"datePublished\":\"2026-03-18T06:06:52+00:00\",\"dateModified\":\"2026-03-18T06:06:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59850\"},\"wordCount\":523,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59850#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1804.webp\",\"keywords\":[\"AstraZeneca\",\"Cancer\",\"NASDAQ: AZN\",\"PD-1\\\/L1\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59850#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59850\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59850\",\"name\":\"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59850#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59850#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1804.webp\",\"datePublished\":\"2026-03-18T06:06:52+00:00\",\"dateModified\":\"2026-03-18T06:06:53+00:00\",\"description\":\"AstraZeneca PLC (NASDAQ: AZN) announced European Union marketing approval for Imfinzi (durvalumab) in combination with FLOT chemotherapy for resectable early\u2011stage and locally advanced gastric cancer and gastroesophageal junction (GEJ) cancer, expanding the PD\u2011L1 inhibitor's perioperative oncology portfolio with demonstrated survival benefits across all PD\u2011L1 expression levels.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59850#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59850\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59850#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1804.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1804.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59850#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca PLC (NASDAQ: AZN) announced European Union marketing approval for Imfinzi (durvalumab) in combination with FLOT chemotherapy for resectable early\u2011stage and locally advanced gastric cancer and gastroesophageal junction (GEJ) cancer, expanding the PD\u2011L1 inhibitor's perioperative oncology portfolio with demonstrated survival benefits across all PD\u2011L1 expression levels.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59850","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial","og_description":"AstraZeneca PLC (NASDAQ: AZN) announced European Union marketing approval for Imfinzi (durvalumab) in combination with FLOT chemotherapy for resectable early\u2011stage and locally advanced gastric cancer and gastroesophageal junction (GEJ) cancer, expanding the PD\u2011L1 inhibitor's perioperative oncology portfolio with demonstrated survival benefits across all PD\u2011L1 expression levels.","og_url":"https:\/\/flcube.com\/?p=59850","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-18T06:06:52+00:00","article_modified_time":"2026-03-18T06:06:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1804.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59850#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59850"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial","datePublished":"2026-03-18T06:06:52+00:00","dateModified":"2026-03-18T06:06:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59850"},"wordCount":523,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59850#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1804.webp","keywords":["AstraZeneca","Cancer","NASDAQ: AZN","PD-1\/L1","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59850#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59850","url":"https:\/\/flcube.com\/?p=59850","name":"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59850#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59850#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1804.webp","datePublished":"2026-03-18T06:06:52+00:00","dateModified":"2026-03-18T06:06:53+00:00","description":"AstraZeneca PLC (NASDAQ: AZN) announced European Union marketing approval for Imfinzi (durvalumab) in combination with FLOT chemotherapy for resectable early\u2011stage and locally advanced gastric cancer and gastroesophageal junction (GEJ) cancer, expanding the PD\u2011L1 inhibitor's perioperative oncology portfolio with demonstrated survival benefits across all PD\u2011L1 expression levels.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59850#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59850"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59850#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1804.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1804.webp","width":1080,"height":608,"caption":"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59850#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer \u2013 Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1804.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59850"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59850\/revisions"}],"predecessor-version":[{"id":59854,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59850\/revisions\/59854"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59853"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}